

The specification has been amended solely to introduce the appropriate sequence identifiers (i.e., the SEQ ID NOs) in the accompanying Sequence Listing. Thus, no new matter has been introduced in this amendment. Entry of this amendment is therefore respectfully requested.

If there are any other issues remaining which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

Respectfully submitted,

Marc S. Gross

Registration No. 19,614 Attorney for Applicant(s)

DARBY & DARBY, P.C. 805 Third Avenue New York, N.Y. 10022 Phone (212) 527-7700

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR **DEPOSIT ACCOUNT NO. 04-0100** 

Customer No.:

Name (Print)

Signature

PATENT TRADEMARK OFFICE

Docket No: 4703/0J586

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Shuji KITAMURA; Takashi UEYAMA

Serial No.: 09/889,313

Art Unit:

TBA

Filed: July 11, 2001

Examiner:

**TBA** 

Process for Producing Fermented Milk Containing Angiotensin Converting

Enzyme Inhibitory Peptide and Process for Producing Milk Serum

## MARK-UP FOR SECOND PRELIMINARY AMENDMENT UNDER 37 C.F.R. 1.111

## In the specification

On page 1, line 21 please amend to read:

ACE acts on angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Pro-Phe-His-Leu) (SEQ ID NO: 1), which has been generated by digestion with renin, to release a dipeptide (His-Leu) from its C-terminal, thereby giving angiotensin II, which causes contraction of vascular smooth muscle and has strong hypertensive effect.

> I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by Express Call Pass Office